S&P 500
7,401.00
+0.91%
Dow Jones
49,665.70
+0.19%
Nasdaq 100
29,241.00
+2.43%
Russell 2000
2,860.88
+0.82%
FTSE 100
10,263.70
+0.48%
Nikkei 225
63,767.70
+2.68%

Investing

FDA OKs Generic Version of Lilly Drug (LLY)

Photo of Paul Ausick
By Paul Ausick Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Indian drug maker Sun Pharmaceutical Industries Ltd. has received approval from the US Food and Drug Administration to sell its generic version of Zyprexa Zydis tablets in the the US. Eli Lilly & Co. (NYSE: LLY) lost patent protection on the anti-psychotic drug in October last year.

The market for generic Zyprexa, or olanzapine, totals about $360 million annually. The drug is used to treat schizophrenia and bipolar disorder. Lilly cut its revenue estimate for 2012 by $3 billion due to the loss of the company’s patent protection on Zyprexa.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Paul Ausick |

Lilly’s Drugs Closer to Edge of Patent Cliff (LLY, PFE, JNJ, BMY, SNY, MRK)

Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better…

Paul Ausick |

Profits to Fall Sharply at Lilly (LLY)

Profits at Eli Lilly & Co. (NYSE: LLY) in 2012 will be sharply lower than analysts had been expecting. The…

Douglas A. McIntyre |

Lipitor OTC: What Next? (PFE, MRK, AZN, SNY, BMY, LLY, JNJ, AMGN)

Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability.…

Trey Thoelcke |

Generics Take a Bite of Eli Lilly Q3 Results

Eli Lilly (NYSE: LLY) this morning reported disappointing third-quarter results as generic drugs took a toll on its sales. The…

Paul Ausick |

Lilly Earnings Dive on Patent Expiration (LLY)

Drug maker Eli Lilly & Co. reported fourth quarter and full year earnings this morning, and although revenues were higher…

Trey Thoelcke |

Teva Secures Rights to Launch Generic Viagra

ThinkstockPfizer Inc.’s (NYSE: PFE) patent protecting popular erectile dysfunction drug Viagra from generic competition may not expire until April 2020,…

Paul Ausick |

Top 10 U.S. Drugs for 2012 First Quarter

Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for…

3 Generic Drug Stocks to Watch Amid Improving Market Prospects
247patrick |

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

Generic price erosion in the United States is expected to continue for the rest of the year.

Paul Ausick |

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

When the American Society of Clinical Oncology (ASCO) decided to create a rating scale for cancer drugs, it certainly must…

Top Gaining Stocks

Akamai
AKAM • Vol: 21,556,944
Micron Technology
MU • Vol: 65,135,624
Intel
INTC • Vol: 227,504,426
Monster Beverage
MNST • Vol: 15,284,847
Dell Technologies
DELL • Vol: 12,167,525

Top Losing Stocks

Mettler Toledo International
MTD • Vol: 539,266
Motorola Solutions
MSI • Vol: 3,101,643
Expedia
EXPE • Vol: 4,189,786
Coterra Energy
CTRA • Vol: 73,319,495
Fidelity National Information Services
FIS • Vol: 11,468,820